Research and Markets has announced the addition of the "Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016" report to their offering.
Charcot-Marie-Tooth Disease pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities Institutes. Our latest report Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Charcot-Marie-Tooth Disease Charcot Marie Tooth disease is a group of hereditary disorders that damage the nerves in arms and legs (peripheral nerves). Symptoms include high foot arches, loss of muscle bulk in legs and feet, curled toes, frequent tripping or falling and decreased ability to run. Risk factors include diabetes and family history. The molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Charcot-Marie-Tooth Disease and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/kzlsln/charcotmarietoot
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005703/en/Business Wire
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.